Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patterning definitive hematopoietic stem cells from embryonic stem cells.

Claudia Lengerke1, George Q Daley

  • 1Department of Hematology and Oncology, University Medical Center II, Tuebingen, Germany.

Experimental Hematology
|September 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Journal of hematology & oncology·2026
Same author

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Journal for immunotherapy of cancer·2026
Same author

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.

Neoplasia (New York, N.Y.)·2026
Same author

Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.

Rheumatology (Oxford, England)·2026
Same author

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Blood advances·2026
Same author

Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma.

Scientific reports·2026
Same journal

Multidisciplinary Characterization of Rare MPL Y591 and R592 Variants in Myeloid Disorders: From Clinical Correlation and Literature-Based Evidence to In Silico Predictors and Structural Bioinformatics.

Experimental hematology·2026
Same journal

Integrin alpha 4 inhibition prolongs the survival of NSG mice engrafted with CD19-negative post-CART19 relapsed B-ALL.

Experimental hematology·2026
Same journal

RNA Binding Protein PCBP1 Functions in the Endothelial-to-Hematopoietic Transition During Hematopoietic Stem Cell Formation.

Experimental hematology·2026
Same journal

Image-enabled cell sorting permits prospective isolation of primitive hematopoietic stem cell subsets with distinct functional potential.

Experimental hematology·2026
Same journal

Inhibition of MLLT1 Limits Growth of KMT2A::AFF1 Leukemias Without Killing Healthy Hematopoietic Stem Cells.

Experimental hematology·2026
Same journal

Adaptive Immune Remodeling in Sickle Cell Disease: Linking Hemolysis-Driven Inflammation to Immune Dysfunction.

Experimental hematology·2026
See all related articles

Researchers are working to derive functional hematopoietic stem cells (HSCs) from embryonic stem cells (ESCs). This research aims to improve cell-based therapies for blood disorders and understand blood formation genetics.

Area of Science:

  • Developmental Biology
  • Stem Cell Biology
  • Hematopoiesis

Background:

  • Embryonic stem cells (ESCs) are derived from blastocysts and possess pluripotency, mirroring early embryonic epiblast cells.
  • ESCs spontaneously differentiate in vitro, making them valuable for studying development and for cell-based therapies.
  • Hematopoietic stem cells (HSCs) are crucial for blood formation and are a target for regenerative medicine.

Purpose of the Study:

  • To derive functional, multipotent, and engraftable HSCs from ESCs.
  • To investigate genetic pathways controlling blood formation.
  • To establish a foundation for engineered ESC-based hematopoietic cell replacement therapies.

Main Methods:

  • Reviewing current progress in hematopoietic differentiation from murine and human ESCs.

Related Experiment Videos

  • Analyzing the underlying mechanisms of hematopoietic cell fate specification.
  • Outlining a strategy for directed HSC differentiation.

    • Main Results:

    • Significant progress has been made in hematopoietic differentiation from ESCs.
    • Understanding of the mechanisms specifying hematopoietic cell fate remains primitive.
    • Capacity to direct definitive HSC differentiation for clinical use is limited.

    Conclusions:

    • Directed differentiation of HSCs from ESCs is essential for clinical applications.
    • Further research is needed to overcome current limitations in HSC derivation.
    • This work aims to enable clinical scale-up and disease-specific applications for HSC therapies.